摘要
目的探讨脉管复康胶囊与甲钴胺片联合治疗后对糖尿病周围神经病变(DPN)患者血清同型半胱氨酸(Hcy)、胱抑素C(CysC)、超敏C反应蛋白(hs-CRP)水平的影响。方法选取在我院内分泌科就诊的2型糖尿病且合并周围神经病变患者180例,区组随机化分为单药治疗组(A组)、联合治疗组(B组)和对照组(C组)三组,每组60例。单药治疗组服用脉管复康胶囊1.8 g,每天3次;联合治疗组服用脉管复康胶囊1.8 g,每天3次,甲钴胺片0.5 mg,每天3次;对照组服用甲钴胺片0.5 mg,每天3次,治疗时间为6个月。于服药前和服药后检测相关生化指标,分析DPN患者血清Hcy、CysC、hs-CRP的变化情况。最后完成研究的病例数分别为A组56例,B组54例,C组57例。结果组内比较中,治疗后Hcy、CysC、hs-CRP水平均较治疗前下降且差异有统计学意义(P <0.05);组间比较中,治疗前三组Hcy、CysC、hs-CRP比较差异无统计学意义(P> 0.05);治疗后三组Hcy、CysC、hs-CRP均较治疗前降低,单药治疗组较对照组三项指标下降明显(P <0.05),联合治疗组比对照组指标降低更显著且差异有统计学意义(P <0.05)。结论脉管复康胶囊能够降低DPN患者Hcy、CysC、hs-CRP水平,联合甲钴胺片效果更佳,有利于临床使用。
Objectives The study was to investigate the effect of Maiguanfukang capsules combined with mecobalamin tablets on serum homocysteine(Hcy),cystatin c(cysc)and high sensitivity C-reactive protein(hs CRP)levels in patients with diabetic peripheral neuropathy(DPN).Methods A total of 180 patients with type 2 diabetes and peripheral neuropathy were selected from the department of endocrinology in our hospital.All patients were randomly divided into single drug treatment group(group A),combined treatment group(group B)and con trol group(group C),including 60 cases in each group.The monotherapy group received 1.8g Maiguanfukuang capsules orally three times a day,while the combined treatment group was additionally given 0.5mg mecobalamin tablets orally three times a day.The control group took 0.5mg mecobalamin tablets orally three times a day.All groups were treated for six months.The levels of Hcy,CysC and hs-CRP in the three groups were measured and analyzed before and after treatment.The number of cases that completed the study was 56 in group A,54 in group B and 57 in group C.Results In the intra-group comparison,the levels of Hcy,CysC and hs-CRP after treat ment were lower than that before treatment with statistical significance(P<0.05).In the inter-group comparison,there was no difference in Hcy,CysC and hs-CRP levels among the three groups before treatment(P >0.05).Af ter treatment,Hcy,CysC and hs-CRP in the three groups were lower.Compared with the control group,the Hcy,CysC and hs-CRP levels of the single drug treatment group decreased significantly(P<0.05),while levels of thecombined treatment group reduced more significantly with statistical significance(P<0.05).Conclusions Mai guanfukang capsules can reduce the levels of Hcy,CysC and hs-CRP in DPN patients,which is worthy of clinical application.
作者
彭少林
杨水冰
杨井金
陆小玉
张玲
杨娇娇
唐维
岳成思
杨康
熊静妮
李珏笛
张美彪
PENG Shaolin;YANG Shuibing;YANG Jingjin;LU Xiaoyu;ZHANG Ling;YANG Jiaojiao;TANG Wei;YUE Chengsi;YANG Kang;XIONG Jingni;LI Juedi;ZHANG Meibiao(Department of Endocrinology and metabolism,First People′s Hospital of Huaihua City,Huaihua 418000,China)
出处
《实用医学杂志》
CAS
北大核心
2019年第2期221-225,共5页
The Journal of Practical Medicine
基金
湖南省中医药管理局科研计划项目(编号:201689)
